argenx
Clinical trials sponsored by argenx, explained in plain language.
Biopharmaceutical company developing antibody therapies for autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to replace IVIg for nerve disease Results expected Sep 2026 (estimated) May already have reported ↗
- Can a Pen-Style injector match a syringe for delivering efgartigimod? Results expected Sep 2026 (estimated)
- New shot shows promise for long-term platelet control in rare bleeding disorder Results expected Oct 2026 (estimated) May already have reported ↗
- New drug hopes to tame rare muscle and skin disease Results expected Nov 2026 (estimated)
- Scientists test how body weight influences a new drug's absorption Results expected Dec 2026 (estimated)
-
Can a new biologic slow kidney damage in IgA nephropathy?
Disease control Not yet recruitingThis phase 2 trial is investigating whether an experimental drug called ARGX-121 can improve outcomes for adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants will receive either ARGX-121 or a placebo, while continuing their usual care. The …
Phase 2 • Sponsor: argenx • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a second antibody drug help Guillain-Barré patients walk again sooner?
Disease control Not yet recruitingGuillain-Barré syndrome (GBS) is a rare condition where the immune system attacks nerves, causing weakness that can progress to paralysis. Standard treatment is intravenous immunoglobulin (IVIg), but recovery is often slow. This phase 2 trial tests whether adding an experimental …
Phase 2 • Sponsor: argenx • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a new injection calm Sjogren's nerve damage?
Disease control Not yet recruitingThis trial tests whether an experimental drug called efgartigimod can reduce nerve damage and pain in adults with Sjogren's disease. Participants will receive either the drug or a placebo as a subcutaneous injection. The study measures changes in neuropathy symptoms and quality o…
Phase 2 • Sponsor: argenx • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new infusion ease muscle weakness in rare genetic disorders?
Disease control Not yet recruitingThis Phase 3 trial is testing whether an experimental drug called adimanebart can help people aged 12 and older with certain congenital myasthenic syndromes (CMS) feel better and do daily activities more easily. Participants are randomly assigned to receive either adimanebart or …
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for teens with rare nerve disease: drug trial launches
Disease control Not yet recruitingThis study tests a new medicine called empasiprubart in teenagers aged 12 to 17 who have a rare nerve disease called CIDP. The goal is to find the right dose and see if the drug is safe and helps control the disease. Participants will receive the drug for about 27 months and be f…
Phase 2/3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC